MX2020008082A - Compuestos y composiciones para el tratamiento del dolor. - Google Patents

Compuestos y composiciones para el tratamiento del dolor.

Info

Publication number
MX2020008082A
MX2020008082A MX2020008082A MX2020008082A MX2020008082A MX 2020008082 A MX2020008082 A MX 2020008082A MX 2020008082 A MX2020008082 A MX 2020008082A MX 2020008082 A MX2020008082 A MX 2020008082A MX 2020008082 A MX2020008082 A MX 2020008082A
Authority
MX
Mexico
Prior art keywords
pain
treatment
compounds
compositions
relates
Prior art date
Application number
MX2020008082A
Other languages
English (en)
Inventor
Martine Schmitt
Jacques Bricard
Frédéric Simonin
Jean- Jacques Bourguignon
Frédéric Bihel
Khadija Elhabazi
Original Assignee
Univ Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Strasbourg filed Critical Univ Strasbourg
Publication of MX2020008082A publication Critical patent/MX2020008082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos, a derivados de piridina y a composiciones farmacéuticas que los contienen para su uso en el tratamiento del dolor. También se refiere a compuestos específicos, composiciones que los comprenden y usos de los mismos, en particular en el tratamiento del dolor.
MX2020008082A 2018-02-05 2019-02-05 Compuestos y composiciones para el tratamiento del dolor. MX2020008082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305117 2018-02-05
PCT/EP2019/052810 WO2019149965A1 (en) 2018-02-05 2019-02-05 Compounds and compositions for the treatment of pain

Publications (1)

Publication Number Publication Date
MX2020008082A true MX2020008082A (es) 2020-09-24

Family

ID=61198781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008082A MX2020008082A (es) 2018-02-05 2019-02-05 Compuestos y composiciones para el tratamiento del dolor.

Country Status (11)

Country Link
US (1) US20210221784A1 (es)
EP (1) EP3749305A1 (es)
JP (2) JP7506379B2 (es)
KR (1) KR20200118005A (es)
CN (1) CN111683660A (es)
AU (1) AU2019213484A1 (es)
BR (1) BR112020014146A2 (es)
CA (1) CA3086668A1 (es)
IL (1) IL276228A (es)
MX (1) MX2020008082A (es)
WO (1) WO2019149965A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220044721A (ko) * 2019-08-06 2022-04-11 도메인 테라퓨틱스 신경펩타이드 ff 수용체 길항제로서의 5-헤테로아릴-피리딘-2-아민 화합물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3637829A1 (de) 1986-11-06 1988-05-11 Asta Pharma Ag Neue 2,6-diamino-3-halogenobenzylpyridine und verfahren zu ihrer herstellung sowie ihre verwendung in pharmazeutika
WO1994014780A1 (en) * 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
FR2814367B1 (fr) 2000-09-25 2008-12-26 Inst Nat Sante Rech Med Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
NZ552398A (en) * 2004-07-28 2010-08-27 Hoffmann La Roche Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors for treatment of diabetes
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
GB0700786D0 (en) * 2007-01-15 2007-02-21 Pfizer Ltd Morpholine dopamine agonists for the treatment of pain
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
GEP20125379B (en) * 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
TW200932219A (en) * 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
GB0812641D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013052393A1 (en) * 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. 3-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9475816B2 (en) * 2012-09-07 2016-10-25 Takeda Pharmaceutical Company Limited Substituted-1,4-dihydropyrazolo[4,3-b]indoles
WO2015066697A1 (en) * 2013-11-04 2015-05-07 Forum Pharmaceuticals Inc. Fused morpholinopyrimidines and methods of use thereof
GB201322334D0 (en) * 2013-12-17 2014-01-29 Agency Science Tech & Res Maleimide derivatives as modulators of WNT pathway
US10214527B2 (en) * 2015-09-03 2019-02-26 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase

Also Published As

Publication number Publication date
US20210221784A1 (en) 2021-07-22
JP2021512946A (ja) 2021-05-20
CA3086668A1 (en) 2019-08-08
AU2019213484A1 (en) 2020-07-02
WO2019149965A1 (en) 2019-08-08
KR20200118005A (ko) 2020-10-14
JP2024113149A (ja) 2024-08-21
CN111683660A (zh) 2020-09-18
IL276228A (en) 2020-09-30
BR112020014146A2 (pt) 2020-12-08
JP7506379B2 (ja) 2024-06-26
EP3749305A1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
PH12018501084B1 (en) Heterocyclic compounds as immunomodulators
WO2019032662A8 (en) Clec9a binding agents and use thereof
EP4302834A3 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
NZ757081A (en) Somatostatin modulators and uses thereof
MY200962A (en) Amide Derivatives As Nav1.7 And Nav1.8 Blockers
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
MY207469A (en) Therapeutic compounds
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX378607B (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12018502139A1 (en) Phosphaplatin liquid formulations
PH12017501668A1 (en) Bace1 inhibitors
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
EA201991746A1 (ru) Производные пиразола в качестве ингибиторов бромодомена